Area of research
Hepatology · Epidemiology
Research interest
Research interests include Liver Disease Diagnosis and Treatment, Liver Disease and Transplantation, Hepatocellular Carcinoma Treatment and Prognosis, and Hepatitis C virus research.
Clinical Care Pathway for the Risk Stratification and Management of Patients With Metabolic Dysfunction–Associated Steatotic Liver Disease
Evolving burden of metabolic dysfunction-associated steatotic liver disease and its complications in a US nationwide healthcare system.
Development and validation of risk stratification models for hepatocellular cancer: A framework from the translational liver cancer consortium.
Validation of Texas Hepatocellular Carcinoma Consortium Risk Index in the Hepatocellular Carcinoma Early Detection Strategy Study
Metabolic Dysfunction–Associated Steatotic Liver Disease (MASLD) in People With Diabetes: The Need for Screening and Early Intervention. A Consensus Report of the American Diabetes Association
The People-First Liver Charter
A Survey Study of Roadblocks in Translational Science.
Corticosteroids in severe alcohol-associated hepatitis. Not so fast: A systematic review of randomized controlled trials.
Metabolic dysfunction-associated steatotic liver disease: Update and impact of new nomenclature on the American Association for the Study of Liver Diseases practice guidance on nonalcoholic fatty liver disease.
Resmetirom therapy for metabolic dysfunction-associated steatotic liver disease: October 2024 updates to AASLD Practice Guidance
Resmetirom therapy for metabolic dysfunction-associated steatotic liver disease: October 2024 updates to AASLD Practice Guidance
GLP-1 Receptor Agonists and Risk for Cirrhosis and Related Complications in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease
The future of International Classification of Diseases coding in steatotic liver disease: An expert panel Delphi consensus statement
Hepatocellular Carcinoma Screening in a Contemporary Cohort of At-Risk Patients
Serum biomarker signature is predictive of the risk of hepatocellular cancer in patients with cirrhosis.
A multisociety Delphi consensus statement on new fatty liver disease nomenclature
A multisociety Delphi consensus statement on new fatty liver disease nomenclature
A multisociety Delphi consensus statement on new fatty liver disease nomenclature
Global trends in hepatocellular carcinoma epidemiology: implications for screening, prevention and therapy
Reply: A multi-society Delphi consensus statement on new fatty liver disease nomenclature
Metabolic dysfunction–associated steatotic liver disease: Update and impact of new nomenclature on the American Association for the Study of Liver Diseases practice guidance on nonalcoholic fatty liver disease
Hepatocellular carcinoma surveillance — utilization, barriers and the impact of changing aetiology
Risk factors for HCC in contemporary cohorts of patients with cirrhosis.
Actionable Solutions to Achieve Health Equity in Chronic Liver Disease
Targets and study design for symptom-focused trials aimed at patients with cirrhosis: An expert consensus.
Long-term outcomes and trends in liver transplantation for hereditary hemochromatosis in the United States.
Posttransplant outcomes for alcohol-associated liver disease during the COVID-19 pandemic.
The Performance of AFP, AFP-3, DCP as Biomarkers for Detection of Hepatocellular Carcinoma (HCC): A Phase 3 Biomarker Study in the United States
AASLD Practice Guidance: Palliative care and symptom‐based management in decompensated cirrhosis
Risk factors for HCC in contemporary cohorts of patients with cirrhosis